# RADIOLABELED MONOCLONAL ANTIBODIES FOR CANCER THERAPY

> **NIH NIH R01** · OAK RIDGE ASSOCIATED UNIVERSITIES · 1987 · $136,593

## Abstract

Monoclonal antibodies and monoclonal antibody fragments with high
specificities for human malignancies will be covalently coupled to DTPA via
the cyclic DTPA anhydride technique to provide a means for labeling such
agents with polyvalent metal radionuclides.  The potential of
radioimmunotherapy using monoclonal antibodies labeled with the
alpha-emitting radionuclide fermium-255, (T1/2 = 20.1 h) and beta-emitting
yttrium-90, T1/2 = 64.2 h) will be studied preclinically.  Two
gastrointestinal monoclonal antibodies with specificity for both colorectal
and pancreatic carcinomas, 1083-17-1A (17-1A) and 1116-NS-19-9 (19-9), and
a monoclonal antimelanoma antibody, 691-19-19 (19-19), will be
investigated.  Antibodies derivatized via the bifunctional chelate
technique will be tested by a radioimmunoassay technique to verify their
retention of immunological activity.  Nude mice bearing the appropriate
tumor type for each monoclonal antibody will be used to test the
specificity of tumor uptake.  Antibodies labeled with the gamma-emitting
radionuclides indium-111, ytterbium-169, and yttrium-88 will be used for
scintigraphic and tissue distribution studies to determine the time course
of the tumor uptake of radiolabeled monoclonal antitumor antibodies.  A
radiolabeled monoclonal anti-influenza antibody will be used to control for
nonspecific binding.  The antibodies will then be labeled with Fm-255 and
Y-90 as well as einsteinium-253 (a longer lived alpha emitter to be used as
a model for Fm-255), and further tissue distribution studies will be
carried out.  These tissue distribution studies will be used for radiation
dosimetry calculations.  In vivo tumor growth studies in nude mice will be
carried out to aid in assessment of the therapeutic potential of Fm255- and
Y90-labeled monoclonal antibody derivatives.  This multidisciplinary
research approach, which combines the fields of bio-organic chemistry,
immunochemistry, and radiopharmacology, is aimed at improving
radioimmunotherapy methods for malignant processes in man.

## Key facts

- **NIH application ID:** 3179055
- **Project number:** 5R01CA039706-03
- **Recipient organization:** OAK RIDGE ASSOCIATED UNIVERSITIES
- **SAM.gov UEI:** JW7MLW3RRK34
- **Principal Investigator:** LEE CROSS WASHBURN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $136,593
- **Award type:** 5
- **Project period:** 1985-09-01 → 1988-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3179055

## Citation

> US National Institutes of Health, RePORTER application 3179055, RADIOLABELED MONOCLONAL ANTIBODIES FOR CANCER THERAPY (5R01CA039706-03). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3179055. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*